248 related articles for article (PubMed ID: 23210501)
1. Thalidomide and its analogues in the treatment of Multiple Myeloma.
Latif T; Chauhan N; Khan R; Moran A; Usmani SZ
Exp Hematol Oncol; 2012 Sep; 1(1):27. PubMed ID: 23210501
[TBL] [Abstract][Full Text] [Related]
2. New immunomodulatory drugs in myeloma.
Lacy MQ
Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.
Terpos E; Kanellias N; Christoulas D; Kastritis E; Dimopoulos MA
Onco Targets Ther; 2013; 6():531-8. PubMed ID: 23690693
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.
Chanan-Khan AA; Swaika A; Paulus A; Kumar SK; Mikhael JR; Rajkumar SV; Dispenzieri A; Lacy MQ
Blood Cancer J; 2013 Sep; 3(9):e143. PubMed ID: 24013664
[TBL] [Abstract][Full Text] [Related]
9. Central neurotoxicity of immunomodulatory drugs in multiple myeloma.
Patel UH; Mir MA; Sivik JK; Raheja D; Pandey MK; Talamo G
Hematol Rep; 2015 Feb; 7(1):5704. PubMed ID: 25852850
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J; Hsu AK; Johnstone RW
Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs in multiple myeloma.
Andhavarapu S; Roy V
Expert Rev Hematol; 2013 Feb; 6(1):69-82. PubMed ID: 23373782
[TBL] [Abstract][Full Text] [Related]
12. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
13. [Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review].
An R; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1888-1891. PubMed ID: 28024514
[TBL] [Abstract][Full Text] [Related]
14. [Pomalidomide for multiple myeloma].
Dougé A; Lemal R; Chaleteix C
Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
16. ARID2 is a pomalidomide-dependent CRL4
Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
[TBL] [Abstract][Full Text] [Related]
17. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist.
McCurdy AR; Lacy MQ
Ther Adv Hematol; 2013 Jun; 4(3):211-6. PubMed ID: 23730498
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
